This study aimed to compare the quality of inpatient (hospitalised) versus outpatient CCE colonic and PIC studies, and to assess factors affecting the outcome.
We performed a retrospective nested case-control study at Tallaght University Hospital, Dublin, Ireland over 1 year. Adult patients who had undergone either an inpatient CCE or PIC were identified from a capsule database. Controls and subjects who had undergone outpatient CCE and PIC procedures during the same period, were sequentially selected, i.e. the next outpatient procedures after the case, in a 1:2 ratio. All participants were ambulatory and able to swallow the capsule. All procedures were performed using PillCam®Colon 2 Capsules (Minneapolis, MN, USA) using a standard bowel preparation and booster regimen. For PIC, the SB sleep mode was manually deselected prior to capsule ingestion. Risk factors for delayed transit were identified at pre-assessment for all outpatients, and if present, patients had a gastric transit assessment at 30 minutes, as per ESGE Technical Review guidance [1 (link), 10 (link)]. Similarly, all inpatients underwent a gastric transit assessment as they are an identified at-risk group. If gastric transit was delayed and in the absence of contra-indications, patients received a prokinetic (metoclopramide 10 mg PO / IV).
Patients took 4 7.5 mg Senna tablets 2 days before the procedure. Then, the evening before the procedure, they ingested the first litre of a two-litre split-dose bowel preparation with Moviprep® (Norgine, Amsterdam, Nederland) a PEG-based solution. The second litre was taken on the morning of the procedure and all procedures were performed before 12:00. The first booster, Moviprep® with 750 ml of water and 15 ml of castor oil, was given when the capsule reached the small bowel. Then, 3 hours later a second booster of Moviprep® with 250 ml of water was given [11 (link)].
All studies were analysed by trained capsule endoscopists using Rapid Reader software version 9.0, and the findings were approved by our institution’s capsule review board. Basic demographics and key outcome measures were identified from the procedure reports and hospital patient records as required. Findings were compared between groups using X [2 (link)] or student t-tests as appropriate, and relevant odds ratio (OR) calculations were performed as indicated. A p-value of < 0.05 was considered significant.
We performed a retrospective nested case-control study at Tallaght University Hospital, Dublin, Ireland over 1 year. Adult patients who had undergone either an inpatient CCE or PIC were identified from a capsule database. Controls and subjects who had undergone outpatient CCE and PIC procedures during the same period, were sequentially selected, i.e. the next outpatient procedures after the case, in a 1:2 ratio. All participants were ambulatory and able to swallow the capsule. All procedures were performed using PillCam®Colon 2 Capsules (Minneapolis, MN, USA) using a standard bowel preparation and booster regimen. For PIC, the SB sleep mode was manually deselected prior to capsule ingestion. Risk factors for delayed transit were identified at pre-assessment for all outpatients, and if present, patients had a gastric transit assessment at 30 minutes, as per ESGE Technical Review guidance [1 (link), 10 (link)]. Similarly, all inpatients underwent a gastric transit assessment as they are an identified at-risk group. If gastric transit was delayed and in the absence of contra-indications, patients received a prokinetic (metoclopramide 10 mg PO / IV).
Patients took 4 7.5 mg Senna tablets 2 days before the procedure. Then, the evening before the procedure, they ingested the first litre of a two-litre split-dose bowel preparation with Moviprep® (Norgine, Amsterdam, Nederland) a PEG-based solution. The second litre was taken on the morning of the procedure and all procedures were performed before 12:00. The first booster, Moviprep® with 750 ml of water and 15 ml of castor oil, was given when the capsule reached the small bowel. Then, 3 hours later a second booster of Moviprep® with 250 ml of water was given [11 (link)].
All studies were analysed by trained capsule endoscopists using Rapid Reader software version 9.0, and the findings were approved by our institution’s capsule review board. Basic demographics and key outcome measures were identified from the procedure reports and hospital patient records as required. Findings were compared between groups using X [2 (link)] or student t-tests as appropriate, and relevant odds ratio (OR) calculations were performed as indicated. A p-value of < 0.05 was considered significant.
Free full text: Click here
